ClinicalTrials.gg
CompletedNCT01199861Updated Jun 19, 2012Results posted

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

A Phase 3 interventional study of Fingolimod and Placebo in Relapsing Multiple Sclerosis, sponsored by Novartis. Completed at 25 sites in 9 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-06-19.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
22nd of 34
138 · median 167
Started
2010
with 3 others
Phase 3
12 of 34
1 open now
Registered
11th of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 22nd largest by enrollment, is one of 4 that started in 2010, is one of 12 in phase 3, and was the 11th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing multiple sclerosis
  • MS
  • Immune response
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have relapsing MS
  • Must have lifetime tetanus vaccination
  • Agree to receive 2010/2011 seasonal influenza vaccine and tetanus toxoid booster injection

Exclusion criteria

Exclusion Criteria:

  • Patients with a type of MS that is not relapsing
  • Patients with history of chronic immune disease
  • Certain cancers
  • Diabetic patients with certain eye disorders
  • Patients who are on certain medications or heart medications
  • Patients with certain heart conditions
  • Patients with certain lung conditions
  • Patients who have already received the 2010/2011 seasonal influenza vaccine

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Fingolimod

    Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.

    Drug: Fingolimod · Biological: Seasonal influenza vaccine · Biological: Tetanus toxoid vaccine

  • Placebo comparator
    Placebo

    Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.

    Drug: Placebo · Biological: Seasonal influenza vaccine · Biological: Tetanus toxoid vaccine

Interventions

  • Fingolimod 0.5 mg capsules for oral administration.

    Also known as: FTY720

  • DrugPlacebo

    Matching placebo capsules for oral administration.

  • BiologicalSeasonal influenza vaccine

    Commercially available injectable influenza vaccine for the 2010/11 influenza season.

    Also known as: Agrippal (TM)

  • BiologicalTetanus toxoid vaccine

    Commercially available tetanus toxoid vaccine booster injection.

    Also known as: Tetanol (TM)

06

What researchers measure

Primary outcomes

  1. Immune Response 3 Weeks After Seasonal Influenza Vaccination

    Percentage of participants who responded to treatment with the seasonal influenza vaccine 3 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.

    Time frame: Week 6 (pre-vaccination) and 3 weeks after vaccination (Study week 9)

Secondary outcomes

  1. Immune Response 6 Weeks After Seasonal Influenza Vaccination

    Percentage of participants who responded to treatment with the seasonal influenza vaccine 6 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.

    Time frame: Week 6 (pre-vaccination) and 6 weeks after vaccination (Study week 12).

  2. Immune Response 3 Weeks After Tetanus Toxoid Booster

    Percentage of participants with an immune response to a single dose of tetanus toxoid three weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.

    Time frame: Week 6 (pre-vaccination) and 3 weeks after vaccination (Study Week 9)

  3. Immune Response 6 Weeks After Tetanus Toxoid Booster

    Percentage of participants with an immune response to a single dose of tetanus toxoid six weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.

    Time frame: Week 6 (pre-vaccination) and 6 weeks after vaccination (Study Week 12)

  4. Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 3 Weeks After Vaccination

    Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo three weeks after a single dose of seasonal influenza vaccine.

    Time frame: Pre-vaccination (Week 6) and 3 weeks after vaccination (Study Week 9).

  5. Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 6 Weeks After Vaccination

    Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo six weeks after a single dose of seasonal influenza vaccine.

    Time frame: Pre-vaccination (Week 6) and 6 weeks after vaccination (Study Week 12).

  6. Number of Participants With Adverse Events (AEs)

    Relationship to study drug was determined by the investigator (suspected/not suspected). A serious AE is defined as an event which fulfills one of the following criteria: * is fatal or life-threatening; * results in persistent or significant disability/incapacity; * constitutes a congenital anomaly/birth defect; * requires inpatient hospitalization or prolongation of existing hospitalization; * is medically significant, i.e., jeopardizes the patient or may require intervention to prevent one of the outcomes listed above.

    Time frame: From first dose of study drug until 45 days after the last dose of study drug (130 days).

07

Results

Posted Jun 19, 2012

Participant flow

Participant flow — Overall Study
MilestoneFingolimodPlacebo
Started9543
Completed9343
Not completed20
Withdrew: Administrative problems10
Withdrew: Adverse event10

Outcome measures

PrimaryImmune Response 3 Weeks After Seasonal Influenza Vaccination

Percentage of participants who responded to treatment with the seasonal influenza vaccine 3 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.

Time frame:
Week 6 (pre-vaccination) and 3 weeks after vaccination (Study week 9)
Reported as:
Number · percentage of participants
Immune Response 3 Weeks After Seasonal Influenza Vaccination
percentage of participantsFingolimodPlacebo
Immune Response 3 Weeks After Seasonal Influenza Vaccination53.383.7
SecondaryImmune Response 6 Weeks After Seasonal Influenza Vaccination

Percentage of participants who responded to treatment with the seasonal influenza vaccine 6 weeks after vaccination. Response was defined as patients fulfilling one of the following criteria for at least one of the three strains contained in the seasonal influenza vaccine: * Seroconversion: The pre-vaccination antibody titer measurement was \<1:10 and the post-vaccination measurement is ≥1:40. * Significant increase in antibody titer: The pre-vaccination antibody titer measurement was ≥1:10 and the increase in antibody titer from this to the post-vaccination measurement is ≥ 4-fold.

Time frame:
Week 6 (pre-vaccination) and 6 weeks after vaccination (Study week 12).
Reported as:
Number · percentage of participants
Immune Response 6 Weeks After Seasonal Influenza Vaccination
percentage of participantsFingolimodPlacebo
Immune Response 6 Weeks After Seasonal Influenza Vaccination43.274.4
SecondaryImmune Response 3 Weeks After Tetanus Toxoid Booster

Percentage of participants with an immune response to a single dose of tetanus toxoid three weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.

Time frame:
Week 6 (pre-vaccination) and 3 weeks after vaccination (Study Week 9)
Reported as:
Number · percentage of participants
Immune Response 3 Weeks After Tetanus Toxoid Booster
percentage of participantsFingolimodPlacebo
Immune Response 3 Weeks After Tetanus Toxoid Booster40.060.5
SecondaryImmune Response 6 Weeks After Tetanus Toxoid Booster

Percentage of participants with an immune response to a single dose of tetanus toxoid six weeks after vaccination. A patient was considered a responder to tetanus toxoid booster vaccination if one of the following criteria was met: 1. Seroconversion: The pre-vaccination antibody titer measurement was \<0.1 IU/ml and the post-vaccination measurement was ≥0.4 IU/ml. 2. Significant increase: The pre-vaccination antibody titer measurement was ≥0.1 IU/ml and the increase in antibody titer from this to the post-vaccination measurement was ≥4- fold.

Time frame:
Week 6 (pre-vaccination) and 6 weeks after vaccination (Study Week 12)
Reported as:
Number · percentage of participants
Immune Response 6 Weeks After Tetanus Toxoid Booster
percentage of participantsFingolimodPlacebo
Immune Response 6 Weeks After Tetanus Toxoid Booster37.548.8
SecondaryChange From Baseline in Seasonal Influenza Vaccine Antibody-titer 3 Weeks After Vaccination

Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo three weeks after a single dose of seasonal influenza vaccine.

Time frame:
Pre-vaccination (Week 6) and 3 weeks after vaccination (Study Week 9).
Reported as:
Number · ratio
Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 3 Weeks After Vaccination
ratioFingolimodPlacebo
A/California/7/09(H1N1)2.454.14
A/Perth/16/2009(H3N2)0.490.36
B/Brisbane/60/20081.342.40
Statistical analysis
  • Fingolimod vs Placebo · Percent inhibition: 41.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
  • Fingolimod vs Placebo · Percent inhibition: -35.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
  • Fingolimod vs Placebo · Percent inhibition: 44.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
SecondaryChange From Baseline in Seasonal Influenza Vaccine Antibody-titer 6 Weeks After Vaccination

Change from Baseline was expressed by the ratio of post-vaccination to pre-vaccination antibody titer for each of the three strains included in the seasonal influenza vaccine. Inhibition of an immune response to each strain included in the seasonal influenza vaccine was assessed by the relative difference of the geometric mean antibody titer ratio on fingolimod as compared to placebo six weeks after a single dose of seasonal influenza vaccine.

Time frame:
Pre-vaccination (Week 6) and 6 weeks after vaccination (Study Week 12).
Reported as:
Number · ratio
Change From Baseline in Seasonal Influenza Vaccine Antibody-titer 6 Weeks After Vaccination
ratioFingolimodPlacebo
A/California/7/09(H1N1)1.812.91
A/Perth/16/2009(H3N2)0.360.28
B/Brisbane/60/20081.082.07
Statistical analysis
  • Fingolimod vs Placebo · Percent inhibition: 38.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
  • Fingolimod vs Placebo · Percent inhibition: -28.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
  • Fingolimod vs Placebo · Percent inhibition: 48.0One minus the back-transformed estimate for the treatment difference was interpreted as the relative inhibition of an immune response caused by fingolimod 0.5 mg compared to placebo; it was presented as a percentage and referred to as 'inhibition'.
SecondaryNumber of Participants With Adverse Events (AEs)

Relationship to study drug was determined by the investigator (suspected/not suspected). A serious AE is defined as an event which fulfills one of the following criteria: * is fatal or life-threatening; * results in persistent or significant disability/incapacity; * constitutes a congenital anomaly/birth defect; * requires inpatient hospitalization or prolongation of existing hospitalization; * is medically significant, i.e., jeopardizes the patient or may require intervention to prevent one of the outcomes listed above.

Time frame:
From first dose of study drug until 45 days after the last dose of study drug (130 days).
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsFingolimodPlacebo
Any adverse event8234
AE related to study drug4211
Serious adverse event12
Adverse events leading to discontinuation10

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fingolimod—1/95 (1.1%)51/95 (53.7%)
Placebo—2/43 (4.7%)22/43 (51.2%)
Most frequent serious events
Most frequent serious events
EventFingolimodPlacebo
Herpes zosterInfections and infestations0/951/43
Hip fractureInjury, poisoning and procedural complications0/951/43
ParaparesisNervous system disorders1/950/43
Most frequent other events
Most frequent other events
EventFingolimodPlacebo
HeadacheNervous system disorders18/954/43
NasopharyngitisInfections and infestations15/958/43
Upper respiratory tract infectionInfections and infestations11/956/43
LymphopeniaBlood and lymphatic system disorders10/950/43
NauseaGastrointestinal disorders2/954/43
CoughRespiratory, thoracic and mediastinal disorders7/950/43
DiarrhoeaGastrointestinal disorders3/953/43
FatigueGeneral disorders3/953/43
Urinary tract infectionInfections and infestations5/952/43

Baseline characteristics

Age Continuous
Age Continuous(years)FingolimodPlaceboTotal
Mean37.4 ± 8.3739.2 ± 8.6737.9 ± 8.48
Age, Customized
Age, Customized(participants)FingolimodPlaceboTotal
18-3025833
31-40351449
41-55352156
Sex: Female, Male
Sex: Female, Male(Participants)FingolimodPlaceboTotal
Female652994
Male301444
08

Study locations

25 sites
  • Novartis Investigative Site
    Aalst, 9300, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liege, 4000, Belgium
  • Novartis Investigative Site
    Wilrijk, 2610, Belgium
  • Novartis Investigative Site
    Nepean, Ontario K2G 6E2, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3A 2B4, Canada
  • Novartis Investigative Site
    Sherbrooke, JiH 5N4, Canada
  • Novartis Investigative Site
    Seinajoki, 60220, Finland
  • Novartis Investigative Site
    Turku, 20100, Finland
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Rennes, 35043, France
  • Novartis Investigative Site
    St Herblain, 44800, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01014, Guatemala
  • Novartis Investigative Site
    Katowice, 40-594, Poland
  • Novartis Investigative Site
    Lodz, 90-153, Poland
  • Novartis Investigative Site
    Madrid, 28029, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Sevilla, 41009, Spain
  • Novartis Investigative Site
    Valencia, 46009, Spain
  • Novartis Investigational Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Nottingham, NG7 2UH, United Kingdom
  • Novartis Investigative Site
    Stoke-on-Trent, ST4 7LN, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2010
First posted
Sep 13, 2010
Start
Aug 2010
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jun 19, 2012
Last update
Jun 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01199861
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
Sep 13, 2010
Start date
Aug 2010
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 19, 2012
Last update
Jun 19, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion